Read the document behind the discussion
The source has a scope.
An offer page, a product label and a research standard answer different questions. This register identifies each document and connects it to the article or open claim record that uses it. An access date records a check; it does not guarantee that terms remain unchanged.
Accessed 2026-09-27
CoreAge Rx Spot On product page
Provider commercial description; named compounded preparation and missing specifications
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
CoreAge Rx Spot On public offer
Provider offer, formula claims, same-product price discrepancy and testimonial disclosure
Read the original sourceWhere the source is discussed
- CoreAge Rx Spot On: what its dark-spot offer actually establishes
- Dark-spot creams: compare the category before the claim
- What a dark-spot cream testimonial can—and cannot—establish
- Two starting prices on one dark-spot cream page: retain the conflict
- Hydroquinone, arbutin and kojic acid belong to exact product records
- Product-label questions that a dark-spot cream review should leave open
Accessed 2026-09-27
Obagi Nu-Derm Clear Fx Skin Brightening Cream
Manufacturer retail product and review record; direct HTML supplements subscription options and terms
Read the original sourceWhere the source is discussed
- Dark-spot creams: compare the category before the claim
- Obagi Clear Fx: the brightening product, price and review display
- What a dark-spot cream testimonial can—and cannot—establish
- Two starting prices on one dark-spot cream page: retain the conflict
- Hydroquinone, arbutin and kojic acid belong to exact product records
- Product-label questions that a dark-spot cream review should leave open
Accessed 2026-09-27
Obagi Nu-Derm Clear prescription cream
Separate manufacturer prescription product record; not Clear Fx identity or quote
Read the original sourceWhere the source is discussed
- Dark-spot creams: compare the category before the claim
- Obagi Clear Fx: the brightening product, price and review display
- What a dark-spot cream testimonial can—and cannot—establish
- Two starting prices on one dark-spot cream page: retain the conflict
- Hydroquinone, arbutin and kojic acid belong to exact product records
- Product-label questions that a dark-spot cream review should leave open
Accessed 2026-09-27
Dermatica: Melasma treatment
Provider possible-ingredient and preparation description; not an individual prescription
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
Dermatica: Pricing
Provider commercial units, support claims and customer stories across different concerns
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
Dermatica US homepage
Provider personalized compound description and current trial offer
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
Dermatica: Terms and conditions
Provider professional-role and service terms; page revision February 4, 2019, freshly accessed
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
FDA: Is it a cosmetic, a drug, or both?
Federal intended-use and category framework; not product-specific regulatory clearance
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
FDA: Compounding and the FDA — Questions and Answers
Federal explanation of nonapproval and evidence boundaries
Read the original sourceWhere the source is discussed
- CoreAge Rx Spot On: what its dark-spot offer actually establishes
- Dark-spot creams: compare the category before the claim
- Dermatica dark-spot treatment: separate the service, formula and stories
- Hydroquinone, arbutin and kojic acid belong to exact product records
- Product-label questions that a dark-spot cream review should leave open
Accessed 2026-09-27
FDA: Potentially harmful OTC skin-lightening products
FDA communication dated April 19, 2022, currently checked; exact approval context and adverse reports
Read the original sourceWhere the source is discussed
- CoreAge Rx Spot On: what its dark-spot offer actually establishes
- Dark-spot creams: compare the category before the claim
- Dermatica dark-spot treatment: separate the service, formula and stories
- What a dark-spot cream testimonial can—and cannot—establish
- Hydroquinone, arbutin and kojic acid belong to exact product records
Accessed 2026-09-27
AAD: Melasma diagnosis and treatment
Professional society assessment and individualized-care context; updated February 15, 2022
Read the original sourceWhere the source is discussed
- CoreAge Rx Spot On: what its dark-spot offer actually establishes
- Dark-spot creams: compare the category before the claim
- Obagi Clear Fx: the brightening product, price and review display
- Dermatica dark-spot treatment: separate the service, formula and stories
- Two starting prices on one dark-spot cream page: retain the conflict
- Hydroquinone, arbutin and kojic acid belong to exact product records
Accessed 2026-09-27
FTC: Health Products Compliance Guidance
Federal advertising evidence guidance; testimonial versus substantiation distinction, not an individual enforcement judgment
Read the original sourceWhere the source is discussed
- CoreAge Rx Spot On: what its dark-spot offer actually establishes
- Dark-spot creams: compare the category before the claim
- Obagi Clear Fx: the brightening product, price and review display
- Dermatica dark-spot treatment: separate the service, formula and stories
- What a dark-spot cream testimonial can—and cannot—establish
- Two starting prices on one dark-spot cream page: retain the conflict
- Hydroquinone, arbutin and kojic acid belong to exact product records
Accessed 2026-09-27
FTC: The Endorsement Guides: What People Are Asking
Official guidance on material connections, exceptional-result impressions and endorsement limitations
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
FDA: Cosmetics Labeling Guide
Cosmetic identity, contents, business and ingredient-declaration context, including order exceptions; not a prescription-label template
Read the original sourceWhere the source is discussed
Accessed 2026-09-27
FDA: Pharmacists Help You Use Medicines Safely
Professional questions about medicine records and conflicting information; no personal compatibility or product-authentication finding
Read the original source